To provide the subject compounds having an affinity for dopamine D2 and D4 receptors, without showing a noted preference for one over the other, also having an affinity for serotonin 5-HT1a, and useful for treatment of mental diseases, e.g. schizophrenia.
The compounds are shown by formula I [A is a 5- to 7-membered heterocyclic group having 1 to 3 hetero atoms selected from the group consisting of O, N and S; R1 is H or fluoro; R2 is a 1-4C alkyl, oxo or the like; (p) is 0 to 2; Z is C or N; broken line is a single bond when Z is N and single or double bond when Z is C; R3 and R4 are each H or a 1-4C alkyl; (n) is 1 or 2; R5 is a 2-, 3- or 4-pyridyl substituted with Y at the meta site for methylene cross-linking; and Y is phenyl or furanyl] and salts thereof, e.g. a compound shown by formula II. The compound shown by formula I is obtained by reacting a compound shown by formula III with a compound shown by the formula; R5-CH2-X (X is an eliminable group).
| JP2006342180 | CHRONIC ASTHMA MEDICINE CONTAINING ANDROSTERONE DERIVATIVE |
| WO/1996/030005 | ANTI-STROKE EFFECTS OF CALCIUM ANTAGONISTS |
| WO/1999/034787 | FAT-BINDING POLYMERS |
LONG STEPHEN K (NL)
DEN HARTOG JACOBUS A J (NL)
FEENSTRA ROELOF W (NL)
KRUSE CORNELIS G (NL)
